HLA-B*5801 carrying station and the correlation of allergic reactions caused by allopurinol
1.Department of Pharmacy, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015; 2.Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
YE Xiaolan1,CHEN Chaosheng2,XU Ren’ai1, et al. HLA-B*5801 carrying station and the correlation of allergic reactions caused by allopurinol[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2015, 45(2): 143-.
Abstract：Objective: To investigate the HLA-B*5801 carrying station and it’s correlation of allergic reactions caused by allopurinol of our hospitalized patients. Methods: The patients’ data from inpatient department were collected, then their HLA-B*5801 was analyzed and detected. Results: There were 100 cases determined the HLA-B*58 allele, and the HLA-B*5801 allele positive cases were 23, including 8 cases with allergic reaction. HLA-B*5801 negative one did not happen allergic reaction. Conclusion: Our patients carried high rate of HLA-B*5801, it will be more safe to detect the gene in time before use allopurinol. But the association between HLA-B*5801 and allergic reaction caused by allopurinol remains further research.
[1]Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol[J]. Proc Natl Acad Sci USA, 2005, 102(11): 4134-4139.
[2]黄玉斌. 381例别嘌醇不良反应分析[J]. 中国药物应用与监测, 2005, 2(1): 32-34.
[3]Weltzien HU, Moulon C, Martin S, et al. T cell immune responses to haptens.Structural models for allergic and auto-immune reactions[J]. Toxicology, 1996, 107(2): 141-151. [4]Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept[J]. Curr Opin Allergy Clin Immunol, 2002, 2(4): 301-305.
[5]Gerber BO, Pichler WJ. Noncovalent interactions of drugs with immune receptors may mediate drug-induced hyper-sensitivity reactions[J]. AAPS J, 2006, 8(1): E160-165.
[6]邓智远, 杨健, 杨文林. 中国大陆汉族别嘌呤醇重症药疹病人HLA-B*5801等位基因的检测[J]. 皮肤性病诊疗学杂志, 2013, 20(6): 379-382.
[7]Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. part1: systematic nonpharmacologic and pharmaco-logic therapeutic approaches to hyperuricemia[J]. Arthritis Care Res(Hoboken), 2012, 64(10): 1431-1446.
[8]Jung JW, Song WJ, Kim YS, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency[J]. Nephrol Dial Transplant, 2011, 26(11): 3567-3572.
[9]Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population[J]. Pharmacogenet Genomics, 2009,19(9): 704-709.
[10]Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial[J]. Arthritis Res Ther, 2010, 12(2): R63.
[11]Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ES-CISIT)[J]. Ann Rheum Dis, 2006, 65(10): 1312-1324.
[12]Stamp LK, Taylor WJ, Jones PB, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol[J]. Arthritis Rheum, 2012, 64(8): 2529-2536.
[13]Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol induced stevens Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis[J]. BMC Med Genet, 2011, 9(12): 118.
